Dr. Grey AI

Kisspeptin-54

Peptide

Kisspeptin-54 (KP-54) is the major circulating isoform of kisspeptin in humans, a 54-amino-acid neuropeptide encoded by the KISS1 gene. It is a critical regulator of reproductive function, acting as the primary stimulator of gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus. Kisspeptin is essential for puberty onset and fertility, and clinical trials have shown promise for its use in IVF treatment, particularly for preventing ovarian hyperstimulation syndrome.

Quick Answer

What it is

Kisspeptin-54 (KP-54) is the major circulating isoform of kisspeptin in humans, a 54-amino-acid neuropeptide encoded by the KISS1 gene. It is a critical regulator of reproductive function, acting as the primary stimulator of gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus.

Key findings

  • Grade A: Oocyte Maturation (IVF) (Infertility)
  • Grade A: Ovarian Hyperstimulation Syndrome Prevention (Infertility)
  • Grade A: LH Secretion (Subfertility)

Safety

  • Phase 2 clinical trial showed kisspeptin-54 effectively triggered oocyte maturation in 95% of women at high risk of OHSS, with embryo formation in 90%.
  • Only 7% of kisspeptin-treated women developed mild OHSS, with no moderate, severe, or critical cases - a significant improvement over standard hCG triggers in high-risk patients.
⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Kisspeptin-54

Quick Facts: Kisspeptin-54

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:9
  • Grade A Findings:5
  • Grade B Findings:3
  • Key Effect:Infertility
A5
B3
C1
D0
2 conditions · 9 outcomes

Detailed Outcomes

A
Oocyte Maturation (IVF)
Phase 2 clinical trial showed kisspeptin-54 effectively triggered oocyte maturation in 95% of women at high risk of OHSS, with embryo formation in 90%.
large↑Improves
A
Ovarian Hyperstimulation Syndrome Prevention
Only 7% of kisspeptin-treated women developed mild OHSS, with no moderate, severe, or critical cases - a significant improvement over standard hCG triggers in high-risk patients.
large↑Improves
A
Egg Maturation Trigger
Kisspeptin-54 successfully triggers egg maturation sufficient for fertilization, embryo implantation, and live birth in IVF patients.
large↑Improves
B
IVF Pregnancy Rate
A single injection of kisspeptin-54 resulted in mature eggs successfully fertilized and transferred, with pregnancy achieved in 23% of subfertile patients undergoing IVF.
moderate↑Improves
A
LH Secretion
Kisspeptin-54 potently stimulates LH release in healthy women and those with hypothalamic amenorrhea, with effects similar to or exceeding exogenous GnRH.
large↑Improves
A
FSH Secretion
Acute kisspeptin administration increases FSH secretion as part of the coordinated gonadotropin response through the hypothalamic-pituitary axis.
moderate↑Improves
B
Reproductive Hormone Recovery (Hypothalamic Amenorrhea)
Twice-weekly kisspeptin-54 administration for 8 weeks stimulated reproductive hormone release in women with hypothalamic amenorrhea, though chronic administration shows tachyphylaxis.
moderate↑Improves